Bio-Rad(BIO) - 2023 Q3 - Earnings Call Transcript

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q3 2023 Results Conference Call October 26, 2023 5:00 PM ET Question-and-Answer Session Jack Meehan - Nephron We have also excluded certain items below the operating line, which are the increase in value of the Sartorius equity securities and loan receivable holdings of $36.4 million, $2.5 million gain from the release of an escrow for an acquisition and about a $700,000 loss associated with venture investments. Thank you, Ilan. So, I guess, I just wanted to take a minu ...